Document is current
Any future updates will be listed below
-
Authors
Hanf, Dorothea
Fasching, Peter
Gass, Paul
Matthias W. Beckmann,
Hack, Carolin C.
Heindl, Felix
Lothar Häberle,
John, Nelson
Erber, Ramona
Press, Michael F.
Rübner, Matthias
Pöschke, Patrik
-
Funding
Funding for this research was provided by:
Universitätsklinikum Erlangen
- License Information
-
More Information
Article History
Received: 13 August 2024
Accepted: 30 October 2024
First Online: 26 November 2024
Declarations
:
: P.A.F. reported receiving personal fees from MacroGenics during the conduct of the study; and grants from Cepheid and personal fees from Novartis, Pfizer, Daiichi Sankyo, AstraZeneca, Eisai, Merck Sharp and Dohme, Lilly, Pierre Fabre, and Seattle Genetics outside the submitted study. R.E. has received honoraria from Roche, Eisai, Pfizer, BioNTech, Veracyte (PRO-CURE), Diaceutics, and Novartis. The institution to which R.E. is affiliated conducts research for AstraZeneca, Roche, Janssen-Cilag, NanoString Technologies, Biocartis, ZytoVision, Novartis, Cepheid, Mindpeak, and BioNTech. C.C.H. has received honoraria from Novartis, Roche, Pfizer, AstraZeneca, Eisai, and Daiichi Sankyo. P.G. has received honoraria from Novartis, MSD, and AstraZeneca. All other authors declare that they do not have any conflicts of interest.
: The ethics committee of Erlangen University Hospital provided approval for the study (ref. numbers 2700 and 297_17_Bc).
: Informed consent was obtained from all of the patients involved in the study.
